Hansoh Pharma (HKEX: 3692) Reports Phase III Weight-Loss Data for Olatorepatide
The Chinese LIGHTEN trial adds another late-stage dataset to the expanding obesity market.
Get analysis like this in your inbox.
Join investors and analysts following Lex Commentary.
Hansoh Pharma has presented Phase III results for olatorepatide, its investigational GLP-1/GIP receptor agonist, at EASD. The disclosure reports average weight loss of 19.3% at 48 weeks in the 15 mg group under the efficacy estimand, compared with 2.7% for placebo.
Under the treatment-regimen estimand, the corresponding figures were 18.7% and 2.5%. LIGHTEN enrolled 604 Chinese adults with overweight or obesity and tested three once-weekly doses against placebo.
Hansoh said China's regulator accepted its weight-management application for review in June. Acceptance starts a review process; it does not confer approval.
The results strengthen the company's evidence package in a large domestic market. They also underline the growing range of obesity programmes emerging from China. Comparisons with other medicines require restraint: differences in population, trial duration and statistical approach can materially affect headline percentages. LIGHTEN supports conclusions about olatorepatide against its own placebo group, rather than a ranking against products tested in separate studies.